PARTNERSHIP OPPORTUNITIES
Partner with Innovators Driving the Next Wave of Inflammasome Therapeutics into the Clinic with Confidence
The 7th Inflammasome Therapeutics Summit brings together 70+ experts from pharma, biotech, and academia who are leading the charge in targeting the inflammasome pathway for next-generation treatments in inflammation, autoimmunity, and neurodegeneration.
With breakthroughs in NLRP3 inhibition, upstream/downstream pathway modulation, and biomarker validation, this is the definitive platform to align your offerings with the most forward-thinking researchers and drug developers in the field.
2025 PARTNERS
Do You Have This Expertise?
- Robust, disease-relevant preclinical models to de-risk early development decision for better clinical efficacy
- Highly sensitive, specific assays and diagnostics to identify reliable biomarkers for data-driven clinical trial design
- Specialized CROs to leverage tailored expertise in inflammasome-targeted screening for accurate candidate selection
Why Partner?
With inflammasome-targeting drug development entering a critical translational phase, your tools and services are essential to helping our scientific leaders overcome key bottlenecks.
This is your opportunity to engage directly with industry and academic decision-makers shaping the future of inflammasome therapeutics and showcase your expertise in providing predictive preclinical models, reliable assays, biomarker strategies, and diagnostic tools that support clear clinical endpoints and robust patient outcomes.
Your solutions can play a critical role in ensuring scientific rigor, accelerating IND-enabling studies, and de-risking clinical progression – ultimately laying the foundation for first-in-class and best-in-class inflammasome-targeted therapies.
Our translational and clinical leaders are looking for:
Validated preclinical models reflective of human inflammasome pathology
Fit-for-purpose assays for pharmacodynamic and MoA readouts
Biomarker and diagnostic platforms to enable patient stratification and endpoint clarity
Specialized CRO support for IND-enabling, toxicology, and translational research